In a phase III randomized controlled trial, 966 patients with mild-to-moderate MASH (stage F1b, F2 or F3) were randomly assigned to once-daily oral treatment with 80 mg or 100 mg resmetirom or placebo for 52 weeks 4
ADA2023 in San Diego: watching the tides roll in
b , View as in a rotated by 180
Wegovy is being launched as Poviztra through a partnership with Emcure Pharma, while Ozempic is being marketed as Extensior in collaboration with Abbott India
Insurance coverage may also play a role for those seeking retatrutide as part of a medical treatment plan, especially as the medication moves through clinical trials and toward potential FDA approval
A physician-led experiment Steven Klein, an addiction medicine specialist at Caron, is leading a pilot program that represents one of the most extensive real-world tests of GLP-1 drugs for addiction to date